Lawmakers reschedule hearing to question Martin Shkreli

Shkreli became the public face of corporate greed last fall, after his company hiked the price of Daraprim, the only approved drug for a rare and sometimes deadly parasitic infection, by 5,000 percent.

[...] the boyish entrepreneur has been deluged with criticism from patients, politicians and the media, with some labeling him the "most hated man in America."

The committee will also hear testimony from Turing's chief commercial officer, Nancy Retzlaff, Valeant Pharmaceutical's interim CEO, Howard Schiller, and experts from government and the private sector.

Daraprim, which Turing acquired in August, is the only approved drug for a life-threatening parasitic infection that mainly strikes pregnant women, cancer patients and AIDS patients.